HomeNewsWorldWHO hopes to have 500 million vaccine doses via COVAX scheme in first quarter of 2021: Chief scientist Soumya Swaminathan

WHO hopes to have 500 million vaccine doses via COVAX scheme in first quarter of 2021: Chief scientist Soumya Swaminathan

To date 189 countries have joined the COVAX programme, which is backed by the WHO and seeks to ensure equitable distribution of vaccines. The United States is not among them, having secured bilateral deals.

December 05, 2020 / 11:32 IST
WHO scientist says trial suspension a 'wake up call': The World Health Organization's chief scientist Soumya Swaminathan said the agency isn't overly worried about the pause in the clinical trials for a coronavirus vaccine developed by Oxford University and AstraZeneca and that the suspension of trial is a wake-up call to the global community to realize there are ups and downs in research.

WHO scientist says trial suspension a 'wake up call': The World Health Organization's chief scientist Soumya Swaminathan said the agency isn't overly worried about the pause in the clinical trials for a coronavirus vaccine developed by Oxford University and AstraZeneca and that the suspension of trial is a wake-up call to the global community to realize there are ups and downs in research.

The World Health Organization hopes to have half a billion doses of COVID-19 vaccines available for distribution by the global COVAX initiative in the first quarter of 2021, its chief scientist said on Friday.

To date 189 countries have joined the COVAX programme, which is backed by the WHO and seeks to ensure equitable distribution of vaccines. The United States is not among them, having secured bilateral deals.

The initial COVAX plan is to vaccinate the 20 percent of populations at highest risk, including health workers and people aged over 65.

"The goal is to get at least 2 billion doses by end of 2021 which will be enough to vaccinate 20 percent of the populations of countries that are part of COVAX," chief scientist Soumya Swaminathan told a Geneva news conference.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

This would be enough to "bring to an end the acute phase of the pandemic" by reducing mortality and the impact on health systems, she said.

"Our goal, our hope is that in the first quarter of 2021 that we would have about half a billion of doses available to be distributed across the countries, in a fair manner," Swaminathan said.

"So countries can start expecting doses toward the end of the first quarter of 2021. A few countries may start earlier, it's likely, possible, that we may have some learnings by going early into a few countries," she said without elaborating.

"But then the majority, the bulk of the tranches would probably start moving out in the second quarter of 2021."

COVAX is co-led by the GAVI vaccines alliance, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI).

Follow our full coverage of the coronavirus pandemic here.

Reuters
first published: Dec 5, 2020 11:21 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347